Deuterated pyrrolopyrimidine compounds as inhibitors of CDK4/6

Details for Australian Patent Application No. 2011217199 (hide)

Owner Novartis AG

Inventors Brain, Christopher Thomas; Perez, Lawrence Blas

Agent Davies Collison Cave

Pub. Number AU-A-2011217199

PCT Pub. Number WO2011/101417

Priority 61/306,248 19.02.10 US

Filing date 17 February 2011

Wipo publication date 25 August 2011

International Classifications

C07D 487/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/519 - ortho- or peri-condensed with heterocyclic rings

A61P 35/00 Antineoplastic agents

C07B 59/00 Introduction of isotopes of elements into organic compounds

Event Publications

30 August 2012 PCT application entered the National Phase

  PCT publication WO2011/101417 Priority application(s): WO2011/101417

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011217206-Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation

2011217190-Method and system for disease diagnosis via simultaneous detection of antibodies bound to synthetic and cellular substrates